reSET-o
FDA approves first prescription mobile app for opioid use disorder, courtesy of Sandoz and Pear Therapeutics
December 11, 2018Manufacturing and Production, Sales and Marketing FDA, Novartis, Pear Therapeutics, app, opioid crisis, opioid epidemic, opioids, pharma, reSET-o
A digital therapeutic launched by Pear Therapeutics and Novartis’ generics and biosimilars division Sandoz has become the first FDA-approved app …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
